Moving forward with immunotherapy: the rationale for anti-CTLA-4 therapy in melanoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Moving forward with immunotherapy: the rationale for anti-CTLA-4 therapy in melanoma

Published:2008-07 Issue:7 Volume:5 Page:367-374
ISSN:1548-5315
Container-title:Community Oncology
language:en
Short-container-title:Community Oncology

Author:

Margolin Kim

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference28 articles.

1. Mechanisms of immune evasion by tumors;Drake;Adv Immunol,2006

2. Cancer immunotherapy: moving beyond current vaccines;Rosenberg;Nat Med,2004

3. Evaluation of immunotherapy in the treatment of melanoma;Faries;Surg Oncol Clin N Am,2006

4. Rituximab (Rituxan) [prescribing information],2007

5. Cetuximab (Erbitux) [prescribing information],2007

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ipilimumab-Induced Sarcoidosis and Thyroiditis;American Journal of Therapeutics;2018-05

2. The Efficacy and Safety of Programmed Cell Death 1 and Programmed Cell Death 1 Ligand Inhibitors for Advanced Melanoma;Medicine;2016-03

3. Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab;Cancer;2013-02-07

4. Complete regression of a previously untreated melanoma brain metastasis with ipilimumab;Melanoma Research;2010-06

5. Immunotherapy of melanoma;Asia-Pacific Journal of Clinical Oncology;2010-03

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP